Methods for enhanced biosynthesis and screening of antibiotics

Patent metadata

Field	Value
Publication number	US-2022380825-A1
Application number	US-202217683343-A
Country	US
Kind code	A1
Filing date	Feb 28, 2022
Priority date	Mar 2, 2021
Publication date	Dec 1, 2022
Grant date	—

Abstract

The present disclosure is directed to devices, instruments, and methods, including automated methods, for enhanced production and efficient screening of biosynthesized antibiotics. More particularly, the present disclosure provides for accelerated biosynthesis and screening on a single-cell scale.

First claim

1 . A cell edited by automated editing, the cell comprising:
an antibiotic production pathway for producing an antibiotic compound; and an antibiotic resistance pathway conferring resistance to the produced antibiotic compound.

2 . The cell of claim 1 , wherein the antibiotic production pathway is a heterologous pathway introduced into to the cell.

3 . The cell of claim 1 , where the antibiotic resistance pathway is a heterologous pathway introduced into to the cell.

4 . The cell of claim 1 , wherein one or more genes in the antibiotic production pathway are under the control of an inducible promoter.

5 . The cell of claim 1 , wherein the cell is a microbial cell.

6 . The cell of claim 5 , wherein the cell is a bacterial cell or fungal cell.

7 . A method of synthesizing an antibacterial compound, comprising:
introducing at least one of an antibiotic production pathway and an antibiotic resistance pathway into each cell of an initial population such that each cell has both the antibiotic production pathway and the antibiotic resistance pathway, the antibiotic production pathway controlled by an inducible promoter; identifying one or more cells of the initial population in which the antibiotic resistance pathway confers resistance to an initial antibiotic compound produced by the antibiotic production pathway when induced; editing the antibiotic production pathway of each identified cell exhibiting resistance to the initial antibiotic compound; selecting one or more cells having the edited antibiotic production pathway that deplete upon induction of the edited antibiotic production pathway, the depletion of the selected cells indicating production of a novel antibiotic compound escaping resistance conferred by the antibiotic resistance pathway; and isolating the novel antibiotic compound from the selected cells.

8 . The method of claim 7 , further comprising:
upon selecting one or more cells that deplete upon induction of the edited antibiotic production pathway, editing the resistance pathway of the selected cells; and identifying one or more selected cells in which the edited antibiotic resistance pathway confers resistance to the novel antibiotic compound produced by the edited antibiotic production pathway when induced.

9 . The method of claim 8 , further comprising:
upon identifying one or more selected cells in which the edited antibiotic resistance pathway confers resistance to the novel antibiotic compound, editing the previously-edited antibiotic production pathway of the selected cells to form a further edited antibiotic production pathway; and screening the selected cells having the further edited antibiotic production pathway for cells that deplete upon induction of the further edited antibiotic production pathway, the depletion of the selected cells indicating production of a second novel antibiotic compound escaping resistance conferred by the edited antibiotic resistance pathway.

10 . The method of claim 7 , wherein introducing at least one of the antibiotic production pathway and the antibiotic resistance pathway is carried out via nucleic-acid guided editing utilizing designed mutagenesis libraries having nucleic acid barcodes.

11 . The method of claim 10 , wherein the cells of the initial population are sequenced before and after introduction of the at least one of the antibiotic production pathway and the antibiotic resistance pathway, and wherein editing events are tracked via the presence or absence of the nucleic acid barcodes.

12 . The method of claim 10 , wherein the designed mutagenesis libraries are further designed to introduce targeted and genome-wide mutagenesis across one or more genes other than the antibiotic production pathway and the antibiotic resistance pathway through edits at up to hundreds of thousands of loci of the cells of the initial population.

13 . The method of claim 7 , wherein editing the antibiotic production pathway of each identified cell exhibiting resistance is carried out via nucleic-acid guided editing utilizing designed mutagenesis libraries having nucleic acid barcodes.

14 . The method of claim 13 , wherein each of the identified cells is sequenced before and after editing the antibiotic production pathway, and wherein editing events are tracked via the presence or absence of the nucleic acid barcodes.

15 . The method of claim 13 , wherein the designed mutagenesis libraries are further designed to introduce targeted and genome-wide mutagenesis across one or more genes other than the antibiotic production pathway and the antibiotic resistance pathway through edits at up to hundreds of thousands of loci of the identified cells.

16 . The method of claim 7 , wherein the antibiotic production pathway is a heterologous pathway introduced into to the cell.

17 . The method of claim 7 , where the antibiotic resistance pathway is a heterologous pathway introduced into to the cell.

18 . The method of claim 7 , wherein the initial population comprises microbial cells.

19 . The method of claim 14 , wherein the initial population comprises bacterial cells.

20 . The method of claim 7 , wherein each cell is sequenced before and/or after each edit applied thereto, and wherein data collected from sequencing of the cells is applied to one or more machine learning algorithms to simulate future edits to the cells.

Assignees

• Inscripta Inc

Inventors

• Shepherd Tyson
• Federowicz Steve
• Held Dan

Classifications

• C12N15/1058 Primary

  Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms · CPC title

• C12R2001/19

  Escherichia coli · CPC title

• C12N2800/101

  for bacteria · CPC title

• C12P21/00 Primary

  Preparation of peptides or proteins (single cell protein C12N1/00) · CPC title

• C12N1/205

  Bacterial isolates · CPC title